Effects of leukocyte inhibitory factor (LIF) on neutrophil phagocytosis and bactericidal activity.
Human leukocyte inhibitory factor (LIF) is a lymphokine initially defined by its ability to inhibit the random migration of neutrophils. We have recently demonstrated that LIF also potentiates a number of f-met-leu-phe-mediated functions as well as enhancing one Fc receptor-mediated function (antibody-dependent cellular cytotoxicity). In this paper, we have extended our studies involving the effects of LIF on the neutrophil, specifically its effect on phagocytosis and bactericidal activity. We demonstrate that LIF (2 U/ml) potentiates phagocytosis of opsonized heat-killed Staphylococcus aureus (up to 57.2%) and sheep erythrocytes (124.4%) as well as unopsonized latex particles (59.9%). Phagocytosis of opsonized sheep erythrocytes was inhibited by an anti-neutrophil Fc receptor antibody with control PMN but not using the LIF-treated PMN. LIF (1/2 to 1 U) also potentiates the killing of S. aureus by up to 51.6%. Higher concentrations of LIF (greater than or equal to 4 U) inhibits killing. These effects were shown not to be associated with an increase in Fc receptor availability. It is therefore possible that potentiation of these neutrophil activities by LIF may occur either as a result of increased receptor turnover or, more likely, secondary to an increase in nonspecific neutrophil adherence. These studies further support the concept that LIF may have an important role in vivo in inflammation and immunity.
D001770:Blood Bactericidal Activity / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D066298:In Vitro Techniques; D008222:Lymphokines / Q000494:pharmacology*; D009504:Neutrophils / Q000502:physiology*; D010587:Phagocytosis / Q000187:drug effects; D011961:Receptors, Fc / Q000276:immunology; D017452:Receptors, IgG
D008222:Lymphokines; D011961:Receptors, Fc; D017452:Receptors, IgG; C010598:leukocyte inhibitory factor